PMID- 22239509
OWN - NLM
STAT- MEDLINE
DCOM- 20120504
LR  - 20181201
IS  - 1365-2893 (Electronic)
IS  - 1352-0504 (Linking)
VI  - 19
IP  - 2
DP  - 2012 Feb
TI  - Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with 
      chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral 
      response.
PG  - e120-5
LID - 10.1111/j.1365-2893.2011.01515.x [doi]
AB  - In chronic hepatitis C (CHC), treatment duration may be individualized according 
      to time to first undetectable hepatitis C virus (HCV) RNA, with patients who 
      attain undetectable HCV RNA early in treatment being candidates for shorter 
      regimens. The aim of this study was to determine the relapse rate in patients 
      with CHC genotype (G) 1 infection and low baseline viral load who achieved 
      undetectable HCV RNA by week 4 [rapid virologic response (RVR)] when treated for 
      24 weeks. This was an open-label, multicentre, noninterventional study. Adult 
      patients with G1 CHC infection and baseline viral load <600,000 IU/mL who 
      attained RVR were treated with peginterferon alfa-2b (1.5 mug/kg/week) plus 
      ribavirin (800-1200 mg/day) for 24 weeks, then followed for a further 24 weeks. 
      The primary endpoint was relapse rate, defined as the proportion of patients with 
      undetectable HCV RNA at treatment week 24 and detectable HCV RNA at week 24 
      follow-up. The secondary efficacy endpoint was sustained virologic response 
      (SVR). Overall, 170 patients were included in the efficacy-evaluable population. 
      The relapse rate was 9.7% (16/165, 95% confidence interval: 0.06-0.15), and SVR 
      was attained by 149 of 170 patients (87.6%). Virologic outcomes were consistent 
      regardless of age, gender, body weight and genotype. Seven patients reported 
      treatment-emergent serious adverse events (AEs), and four patients discontinued 
      treatment because of an AE. This study further demonstrates that peginterferon 
      alfa-2b plus weight-based ribavirin for 24 weeks is an effective treatment 
      strategy for treatment-naive patients with G1 CHC and low viral load who attain 
      RVR.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Craxi, A
AU  - Craxi A
AD  - Sezione di Gastroenterologia & Epatologia, DiBiMIS, University of Palermo, Italy. 
      craxanto@unipa.it
FAU - Koutsounas, S
AU  - Koutsounas S
FAU - Ogurtsov, P
AU  - Ogurtsov P
FAU - Chemello, L
AU  - Chemello L
FAU - Maticic, M
AU  - Maticic M
FAU - Torras, J
AU  - Torras J
FAU - Diago, M
AU  - Diago M
FAU - Tartaglione, M T
AU  - Tartaglione MT
FAU - Witthoeft, T
AU  - Witthoeft T
FAU - Yu, X
AU  - Yu X
FAU - Faruqi, R
AU  - Faruqi R
FAU - Chaudhri, E
AU  - Chaudhri E
FAU - Pedicone, L D
AU  - Pedicone LD
FAU - Zuckerman, E
AU  - Zuckerman E
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110919
PL  - England
TA  - J Viral Hepat
JT  - Journal of viral hepatitis
JID - 9435672
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antiviral Agents/*administration & dosage
MH  - Female
MH  - Genotype
MH  - Hepacivirus/*classification/genetics/*isolation & purification
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/*administration & dosage
MH  - Recombinant Proteins/administration & dosage
MH  - Recurrence
MH  - Ribavirin/*administration & dosage
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Viral Load
MH  - Young Adult
EDAT- 2012/01/14 06:00
MHDA- 2012/05/05 06:00
CRDT- 2012/01/14 06:00
PHST- 2012/01/14 06:00 [entrez]
PHST- 2012/01/14 06:00 [pubmed]
PHST- 2012/05/05 06:00 [medline]
AID - 10.1111/j.1365-2893.2011.01515.x [doi]
PST - ppublish
SO  - J Viral Hepat. 2012 Feb;19(2):e120-5. doi: 10.1111/j.1365-2893.2011.01515.x. Epub 
      2011 Sep 19.